Abstract: A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide using selective crystallization with chiral carboxylic acids.
Abstract: Disclosed are chemical entities which are inhibitors of spleen tyrosine kinase (SYK), namely, chemical entities comprising 6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridine-3(2H)-one and certain solid state forms thereof. Also disclosed are methods of using the chemical entities to treat disorders such as a cancer.
Type:
Grant
Filed:
May 8, 2020
Date of Patent:
June 7, 2022
Assignee:
Calithera Biosciences, Inc.
Inventors:
Rongliang Chen, Tomonori Ichibakase, Chunrong Ma, Christopher F. Matthews, Hajime Motoyoshi, Colin O'Bryan, Kentaro Yaji, Naoki Yoshikawa
Abstract: The disclosure relates to methods of treating or preventing a disease in a subject by conjointly administering to the subject an arginase inhibitor disclosed herein and a composition comprising immune cells disclosed herein.
Type:
Grant
Filed:
November 8, 2017
Date of Patent:
April 5, 2022
Assignee:
CALITHERA BIOSCIENCES, INC.
Inventors:
Amani Makkouk, Matthew I. Gross, Francesco Parlati
Abstract: The invention relates to novel heterocyclic compounds having CD73 inhibitory activity and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
Type:
Grant
Filed:
September 27, 2019
Date of Patent:
December 28, 2021
Assignee:
CALITHERA BIOSCIENCES, INC.
Inventors:
Lijing Chen, Jim Li, Eric B. Sjogren, Roland J. Billedeau
Abstract: The invention relates to novel heterocyclic compounds having CD73 inhibitory activity and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
Type:
Grant
Filed:
September 27, 2019
Date of Patent:
November 16, 2021
Assignee:
CALITHERA BIOSCIENCES, INC.
Inventors:
Lijing Chen, Jim Li, Eric B. Sjogren, Roland J. Billedeau
Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
Type:
Application
Filed:
January 20, 2021
Publication date:
August 26, 2021
Applicant:
CALITHERA BIOSCIENCES, INC.
Inventors:
Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, JR., Lene Raunkjaer PETERSEN
Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
Type:
Grant
Filed:
June 20, 2019
Date of Patent:
August 3, 2021
Assignee:
Calithera Biosciences, Inc.
Inventors:
Lijing Chen, Roland Joseph Billedeau, Jim Li
Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
Type:
Grant
Filed:
December 19, 2019
Date of Patent:
June 15, 2021
Assignee:
Calithera Biosciences, Inc.
Inventors:
Roland J. Billedeau, Jim Li, Lijing Chen
Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
Type:
Grant
Filed:
February 14, 2020
Date of Patent:
June 1, 2021
Assignee:
Calithera Biosciences, Inc.
Inventors:
Eric B. Sjogren, Jim Li, Lijing Chen, Roland J. Billedeau, Timothy F. Stanton, Michael Van Zandt, Darren Whitehouse, Gunnar E. Jagdmann, Jr., Lene Raunkjær Petersen
Abstract: A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide using selective crystallization with chiral carboxylic acids.
Abstract: The invention relates to methods of treating cancer, with a combination of an arginase inhibitor and a chemotherapeutic agent. The invention further relates to methods of assessing efficacy of a cancer treatment by measuring arginine levels in a tumor.
Type:
Application
Filed:
November 19, 2020
Publication date:
March 18, 2021
Applicant:
CALITHERA BIOSCIENCES, INC.
Inventors:
Matthew I. GROSS, Susanne M. STEGGERDA, Weiqun LI
Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
Type:
Grant
Filed:
February 1, 2019
Date of Patent:
March 9, 2021
Assignee:
Calithera Biosciences, Inc.
Inventors:
Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
Type:
Application
Filed:
November 12, 2020
Publication date:
March 4, 2021
Applicant:
CALITHERA BIOSCIENCES, INC.
Inventors:
Eric B. SJOGREN, Jim LI, Michael VAN ZANDT, Darren WHITEHOUSE
Abstract: The invention relates to methods of treating cancer, with a combination of an arginase inhibitor and a chemotherapeutic agent. The invention further relates to methods of assessing efficacy of a cancer treatment by measuring arginine levels in a tumor.
Type:
Grant
Filed:
July 29, 2019
Date of Patent:
February 2, 2021
Assignee:
CALITHERA BIOSCIENCES, INC.
Inventors:
Matthew I. Gross, Susanne M. Steggerda, Weiqun Li
Abstract: A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide using selective crystallization with chiral carboxylic acids.
Type:
Grant
Filed:
November 18, 2019
Date of Patent:
February 2, 2021
Assignee:
Calithera Biosciences, Inc.
Inventors:
Michael C. Van Zandt, Jennifer L. Savoy
Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
Type:
Grant
Filed:
August 10, 2018
Date of Patent:
December 1, 2020
Assignee:
CALITHERA BIOSCIENCES, INC.
Inventors:
Eric B. Sjogren, Jim Li, Michael Van Zandt, Darren Whitehouse
Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
Type:
Grant
Filed:
March 23, 2020
Date of Patent:
November 24, 2020
Assignee:
CALITHERA BIOSCIENCES, INC.
Inventors:
Eric B. Sjogren, Jim Li, Michael Van Zandt, Darren Whitehouse
Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
Type:
Application
Filed:
February 14, 2020
Publication date:
October 29, 2020
Applicant:
CALITHERA BIOSCIENCES, INC.
Inventors:
Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, Lene Raunkjær PETERSEN
Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.
Type:
Grant
Filed:
November 15, 2013
Date of Patent:
October 6, 2020
Assignee:
Calithera Biosciences, Inc.
Inventors:
Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy Friend Stanton, Eric Brian Sjogren
Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
Type:
Application
Filed:
March 23, 2020
Publication date:
July 16, 2020
Applicant:
CALITHERA BIOSCIENCES, INC.
Inventors:
Eric B. SJOGREN, Jim LI, Michael VAN ZANDT, Darren WHITEHOUSE